Research Advances in Therapeutic Strategies and Drug Delivery Systems for Pathological Scars

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Pathological scars are fibrotic lesions that result from aberrant wound healing following tissue injury, such as burns. They are frequently associated with disfigurement and dysfunction, thereby severely impairing the quality of life of affected patients. Current clinical treatments, including surgery, laser therapy, and corticosteroid injections, are often characterized by limited efficacy, high recurrence rates, and undesirable side effects, including skin atrophy. Furthermore, the dense structure and excessive extracellular matrix (ECM) deposition in scar tissue present a significant barrier to effective drug penetration, thereby further limiting therapeutic efficacy. In recent years, biomaterial-based drug delivery systems, which integrate sustained drug release with minimally invasive transdermal technologies, have emerged as a promising strategy to overcome the limitations of traditional therapies. This review systematically outlines the pathogenesis and molecular mechanisms of pathological scars, summarizes established and emerging treatments, and highlights the application strategies and future prospects of novel biomaterial-based drug delivery systems for managing this condition.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.